• European Pharmacopoeia, 6th ed., 2008 and Supplements 6.1 and 6.2 (Fludarabine Phosphate). (pocketdrugguide.com)
  • The United States Pharmacopeia 31, 2008 (Fludarabine Phosphate). (pocketdrugguide.com)
  • Each ml of sterile, injectable liquid contains 25 mg of fludarabine phosphate. (pharmachoice.com)
  • Fludarabine Phosphate Injection, USP contains fludarabine phosphate, a fluorinated nucleotide analog of the antiviral agent vidarabine, 9-ß-D-arabinofuranosyladenine (ara-A) that is relatively resistant to deamination by adenosine deaminase. (guidelinecentral.com)
  • Each mL contains 25 mg of the active ingredient fludarabine phosphate, 25 mg of mannitol, water for injection, q.s., and sodium hydroxide to adjust pH to 6.8. (guidelinecentral.com)
  • Fludarabine Phosphate Injection, USP is a sterile solution intended for intravenous administration. (guidelinecentral.com)
  • The chemical name for fludarabine phosphate is 9 H -Purin-6-amine, 2-fluoro-9-(5- O -phosphono-ß-D-arabinofuranosyl) (2-fluoro-ara-AMP). (guidelinecentral.com)
  • Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. (guidelinecentral.com)
  • Phase I studies in humans have demonstrated that fludarabine phosphate is rapidly converted to the active metabolite, 2-fluoro-ara-A, within minutes after intravenous infusion. (guidelinecentral.com)
  • Limited pharmacokinetic data for fludarabine phosphate for injection are available from a published study of children (ages 1 to 21 years) with refractory acute leukemias or solid tumors (Children's Cancer Group Study 097). (guidelinecentral.com)
  • When fludarabine phosphate for injection was administered as a loading dose over 10 minutes immediately followed by a 5-day continuous infusion, steady-state conditions were reached early. (guidelinecentral.com)
  • Serious opportunistic infections have occurred in CLL patients treated with fludarabine phosphate. (drugcentral.org)
  • Hematologic events (neutropenia, thrombocytopenia, and/or anemia) were reported in the majority of CLL patients treated with fludarabine phosphate. (drugcentral.org)
  • Bone marrow fibrosis occurred in one CLL patient treated with fludarabine phosphate.Several instances of trilineage bone marrow hypoplasia or aplasia resulting in pancytopenia, sometimes resulting in death, have been reported in post-marketing surveillance. (drugcentral.org)
  • The majority of patients rechallenged with fludarabine phosphate developed recurrence in the hemolytic process.In post-marketing experience, cases of myelodysplastic syndrome and acute myeloid leukemia, mainly associated with prior, concomitant or subsequent treatment with alkylating agents, topoisomerase inhibitors, or irradiation have been reported. (drugcentral.org)
  • Serious and sometimes fatal infections, including opportunistic infections and reactivations of latent viral infections such as VZV (herpes zoster), Epstein-Barr virus and JC virus (progressive multifocal leukoencephalopathy) have been reported in patients treated with fludarabine phosphate.Rare cases of Epstein-Barr (EBV) associated lymphoproliferative disorders have been reported in patients treated with fludarabine phosphate.In post-marketing experience, cases of progressive multifocal leukoencephalopathy have been reported. (drugcentral.org)
  • Tumor lysis syndrome has been reported in CLL patients treated with fludarabine phosphate. (drugcentral.org)
  • Peripheral neuropathy has been observed in patients treated with fludarabine phosphate and one case of wrist-drop was reported. (drugcentral.org)
  • Pneumonia, frequent manifestation of infection in CLL patients, occurred in 16%, and 22% of those treated with fludarabine phosphate in the MDAH and SWOG studies, respectively. (drugcentral.org)
  • Pulmonary hypersensitivity reactions to fludarabine phosphate characterized by dyspnea, cough and interstitial pulmonary infiltrate have been observed.In post-marketing experience, cases of severe pulmonary toxicity have been observed with fludarabine phosphate use which resulted in ARDS, respiratory distress, pulmonary hemorrhage, pulmonary fibrosis, pneumonitis and respiratory failure. (drugcentral.org)
  • The recommended dose is 40mg fludarabine phosphate per square metre of body surface area (BSA) given daily for 5 consecutive days at 28 day intervals by the oral route. (medscape.co.uk)
  • Granulocytes 0.5-1.0 x10 to the power of 9 per litre OR platelets 50-100 x10 to the power of 9 per litre, 30mg per square metre per day of fludarabine phosphate is recommended. (medscape.co.uk)
  • Fludarabine is a purine analogue and is metabolized rapidly to F-Ara-ATP, which inhibits DNA synthesis by inhibition of DNA polymerases and prevents elongation of DNA strands through direct incorporation into the DNA molecule. (pocketdrugguide.com)
  • It is a purine nucleoside antimetabolite . (bionity.com)
  • Hydroxyurea, an antineoplastic agent, inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. (targetmol.com)
  • Fludara (fludarabine) is a cancer medication used to treat B-cell chronic lymphocytic leukemia (CLL). (rxlist.com)
  • Our Fludara (fludarabine) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication. (rxlist.com)
  • FLUDARA (fludarabine) FOR INJECTION should be administered under the supervision of a qualified physician experienced in the use of antineoplastic therapy. (rxlist.com)
  • FLUDARA (fludarabine) FOR INJECTION can severely suppress bone marrow function. (rxlist.com)
  • When used at high doses in doseranging studies in patients with acute leukemia , FLUDARA (fludarabine) FOR INJECTION was associated with severe neurologic effects, including blindness, coma, and death. (rxlist.com)
  • Instances of life-threatening and sometimes fatal autoimmune phenomena such as hemolytic anemia , autoimmune thrombocytopenia /thrombocytopenic purpura (ITP), Evans syndrome, and acquired hemophilia have been reported to occur after one or more cycles of treatment with FLUDARA (fludarabine) FOR INJECTION. (rxlist.com)
  • Patients undergoing treatment with FLUDARA (fludarabine) FOR INJECTION should be evaluated and closely monitored for hemolysis . (rxlist.com)
  • Therapy-related AML (t-AML) is a subtype of AML caused by prior treatment with certain antineoplastic drugs (eg, alkylating agents, hydroxyurea , and topoisomerase II inhibitors). (msdmanuals.com)
  • The mechanism of action of this antimetabolite is not completely characterized and may be multi-faceted. (guidelinecentral.com)
  • The program of six courses of fludarabine/cyclophosphamide was administered in 75% of patients and reduced in 19% of patients because of severe myelosuppression and/or sepsis, which was fatal in one patient. (pocketdrugguide.com)
  • In another study, the efficacy of fludarabine/cyclophosphamide in a population of chronic lymphocytic leukemia patients was accurately determined by analyzing response rates according to the patients' treatment history. (pocketdrugguide.com)
  • Methotrexate is an antimetabolite, which inhibits DHFR resulting in decreased immune function and antineoplastic activity and is FDA approved for psoriasis, RA, and several cancers including choriocarcinoma, AML, lung, head and neck and epidermoid (FDA.gov). (jax.org)
  • Fludarabine is a nucleic acid synthesis Inhibitor and a STAT1 activation inhibitor. (targetmol.com)
  • An antimetabolite that is converted to deoxyuridine triphosphate during DNA synthesis. (targetmol.com)
  • In a clinical investigation using fludarabine in combination with pentostatin (deoxycoformycin) for the treatment of refractory chronic lymphocytic leukemia (CLL), there was an unacceptably high incidence of fatal pulmonary toxicity. (guidelinecentral.com)
  • Fludarabine is a nucleotide analogue of vidarabine converted to 2-fluoro-ara-A, which enters the cell and is phosphorylated to form active metabolite 2-fluoro-ara-adenosine triphosphate (ATP). (medscape.com)
  • In popular usage, it usually refers to antineoplastic drugs used to treat cancer or the combination of these drugs into a standardized treatment regimen . (wikidoc.org)
  • The name FluCam has been used for a regimen of fludarabine with alemtuzumab. (pocketdrugguide.com)
  • Seventeen patients had received previous therapy, 6 of whom received fludarabine or fludarabine combinations. (pocketdrugguide.com)
  • Patients relapsed after or were refractory to alkylating agents and failed to achieve a PR with their last fludarabine-based therapy. (pocketdrugguide.com)
  • Previously untreated patients receiving fludarabine monotherapy reportedly achieved an overall response rate of 60-80%, similar to the data presented in this trial. (pocketdrugguide.com)
  • The use of oral fludarabine as a first line treatment, should only be commenced in patients with advanced disease: Rai stages III/IV (Binet stage C) or Rai stages I/II (Binet stage A/B) where the patient has disease related symptoms or evidence of progressive disease. (medscape.co.uk)
  • Therefore, caution should be exercised with the administration of fludarabine in these patients. (medscape.co.uk)
  • There are inadequate data available concerning the use of fludarabine in patients with hepatic impairment. (medscape.co.uk)
  • The manufacturer advises that fludarabine should be used with caution in these patients. (medscape.co.uk)
  • Fludarabine may cause nausea and vomiting, but it is important to keep using it, unless otherwise directed by your doctor. (pharmachoice.com)
  • The recommended dose and dosing schedule of fludarabine varies according to the response to treatment, other medications or treatments being used, and body size. (pharmachoice.com)
  • Instances of life-threatening and sometimes fatal autoimmune hemolytic anemia have been reported to occur after one or more cycles of treatment with fludarabine. (guidelinecentral.com)
  • Pemetrexed is a parenterally administered folate antagonist and antineoplastic agent, used in the treatment of non-small cell lung cancer and malignant mesotheli. (targetmol.com)
  • Treatment of children under 18 years with fludarabine is not recommended by the manufacturer, as its safety and effectiveness have not been established. (medscape.co.uk)
  • Creatinine clearance is less than 30ml/minute : Fludarabine treatment is contraindicated. (medscape.co.uk)
  • Cladribine is a synthetic antineoplastic agent for continuous intravenous (IV) infusion. (medscape.com)
  • Fludarabine is always used under the supervision of a doctor. (pharmachoice.com)
  • It is recommended that fludarabine is administered until the best response is achieved (complete or partial remission, usually 6 cycles) and then the drug should be discontinued. (medscape.co.uk)
  • Fludarabine is used to treat a type of cancer known as chronic lymphocytic leukemia (CLL) for people for whom other treatments have not worked. (pharmachoice.com)
  • Fludarabine causes the death of cancer cells by interfering with their growth and reproduction. (pharmachoice.com)
  • As well as interfering with the genetic material DNA of cancer cells, fludarabine can interfere with some of your normal cells. (pharmachoice.com)
  • Antimetabolites that are useful in cancer chemotherapy. (lookformedical.com)
  • Antimetabolites inhibit cell growth and proliferation. (medscape.com)
  • At present, there is limited data for the use of fludarabine in elderly persons particularly those over 75 years of age. (medscape.co.uk)